48 results on '"Kristensen, L. E."'
Search Results
2. AB1610 NON-PHARMACOLOGICAL AND SELF-MANAGEMENT INTERVENTIONS FOR MAIN OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS: A SYSTEMATIC REVIEW
3. AB1100 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL DISEASE CONTROL CRITERIA WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION, PAIN AND FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM BE OPTIMAL, A PHASE 3 RANDOMISED, PLACEBO-CONTROLLED STUDY
4. AB0750 Back pain and morning stiffness as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
5. POS1018 DRUG SURVIVAL AND TREATMENT RESPONSE RATES IN PSORIATIC ARTHRITIS PATIENTS SWITCHING TO FIRST- OR SECOND-LINE IL-17 INHIBITOR TREATMENT: A DANISH POPULATION-BASED COHORT STUDY
6. OP0302 IS INCREASED RISK OF UROLITHIASIS IN AXIAL SPONDYLOARTHRITIS DRIVEN BY GUT INFLAMMATION? RESULTS FROM THE SPARTAKUS COHORT
7. POS0182 WHO ARE LIKELY TO BENEFIT FROM THE GOOD LIFE WITH OSTEOARTHRITIS IN DENMARK (GLAD) EXERCISE AND EDUCATION PROGRAM? AN EFFECT MODIFIER ANALYSIS OF A RANDOMISED CONTROLLED TRIAL
8. POS1042 IMPACT OF RISANKIZUMAB ON IMPROVING HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, AND REDUCING FATIGUE AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: A POOLED ANALYSIS OF TWO PHASE 3 CLINICAL TRIALS
9. POS1024 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 1
10. AB0897 Impact of risankizumab on improving symptoms and health-related quality of life and reducing fatigue and pain among psoriatic arthritis patients with moderate-to-severe skin involvement: Evidence from two Phase III trials
11. POS1099 QUALITY OF LIFE, WORK IMPAIRMENT, AND DAILY ACTIVITY IMPAIRMENT OF PATIENTS WITH PSORIASIS VERSUS PSORIATIC ARTHRITIS: A REAL-WORLD SURVEY IN US AND EUROPE
12. POS0955 PATIENTS’ PERSPECTIVES ON DISEASE- AND TREATMENT-RELATED ISSUES ARE ESSENTIAL FOR TREATMENT SUCCESS IN PATIENTS WITH SPONDYLOARTHRITIS AND ASSOCIATED DISEASES: A QUALITATIVE CLINICAL CONCEPT MAPPING STUDY
13. POS1470-HPR KNOWING WHAT TO DO WITH THE DATA - A QUALITATIVE STUDY ON CHALLENGES OF USING SMARTPHONE-BASED ePROs IN RHEUMATOID ARTHRITIS
14. POS0076 DRUG SURVIVAL OF BIOLOGICS AND NOVEL IMMUNOMODULATORS FOR RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, AND PSORIASIS - A NATIONWIDE COHORT STUDY FROM THE DANBIO AND DERMBIO REGISTRIES
15. AB1393 RHEUMABUDDY4.0 LEADING THE PATH TO A PATIENT-DRIVEN ELECTRONIC SUPPORT AND MONITORING TOOL
16. AB0879 Interim analysis of baseline characteristics and 12-week outcomes for a subset of patients with moderate-to-severe plaque psoriasis and psoriatic arthritis from the Psoriasis Study of Health Outcomes
17. POS1107 CHANGE IN ULTRASOUND-BASED KNEE JOINT INFLAMMATORY MARKERS AFTER WEIGHT LOSS IN PATIENTS WITH OSTEOARTHRITIS: A PROSPECTIVE COHORT STUDY.
18. OP0103 GENE EXPRESSION PROFILES RETRIEVED FROM SINGLE CELL RNA SEQUENCING REVEAL PHENOTYPIC TRAITS IN PATIENTS WITH PSORIATIC ARTHRITIS INITIATING TUMOUR NECROSIS FACTOR ALPHA INHIBITOR AND INTERLEUKIN-17 INHIBITOR
19. OP0027 ASSOCIATION BETWEEN BASELINE CARDIOVASCULAR RISK AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MALIGNANCIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS RECEIVING TOFACITINIB
20. AB0924 Individual Digit Level Nail Involvement and Joint Assessment in Patients with Nail Psoriasis
21. AB0559 EFFICACY AND SAFETY OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AFTER INADEQUATE RESPONSE OR INTOLERANCE TO DMARDs: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 TRIAL
22. POS0144 NOVEL APPLICATION OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AND NAILFOLD CAPILLAROSCOPY IN PSORIATIC ARTHRITIS - DIAGNOSTIC AND PROGNOSTIC ACCURACY IN RELATION TO PSORIASIS AND HAND OSTEOARTHRITIS
23. POS0237 GUT DYSBIOSIS LINKED TO WORSE DISEASE STATUS IN AXIAL SPONDYLOARTHRITIS
24. THU0619-HPR PREVALENCE OF DISTAL INTERPHALANGEAL JOINT ULTRASONOGRAPHY FEATURES IN PSORIATIC ARTHRITIS, SKIN PSORIASIS, OSTEOARTHRITIS AND HEALTHY INDIVIDUALS: A CROSS-SECTIONAL STUDY
25. PARE0024 AWARENESS ABOUT FAMILY PLANNING AND PREGNANCY EXPECTATION AMONG PATIENTS WITH CHRONIC INFLAMMATORY DISEASE OF THE SKIN OR JOINTS
26. OP0172 EFFECT OF WEIGHT LOSS AND LIRAGLUTIDE ON SERUM URATE LEVELS AMONG OBESE KNEE OSTEOARTHRITIS PATIENTS: SECONDARY ANALYSIS OF A RANDOMISED CONTROLLED TRIAL
27. FRI0592 IMPACT OF INDIVIDUAL SYMPTOMS OF PSORIATIC ARTHRITIS ON PHYSICAL COMPONENT SCORE AND MENTAL COMPONENT SCORE OF SF-36 AS A MEASURE OF HEALTH RELATED QUALITY OF LIFE (QOL): AN OBSERVATIONAL COHORT STUDY
28. THU0394 COMPARISON OF TREATMENT RETENTION OF SECUKINUMAB AND TNF-INHIBITORS IN PSORIATIC ARTHRITIS. OBSERVATIONAL DATA FROM A NORDIC COLLABORATION.
29. FRI0345 HEAD-TO-HEAD STUDY EVALUATING THE COMBINED ACR50/PASI100 TREATMENT RESPONSE OF IXEKIZUMAB VERSUS ADALIMUMAB: INDIVIDUAL PATIENT DATA FROM A RANDOMIZED, OPEN-LABEL STUDY IN BIOLOGIC-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS THROUGH WEEK 52
30. THU0614-HPR ASSESSING THE EFFECT OF INTERVENTIONS FOR AXIAL SPONDYLOARTHRITIS ACCORDING TO THE ENDORSED ASAS/OMERACT CORE OUTCOME SET: A META-RESEARCH STUDY OF TRIALS INCLUDED IN COCHRANE REVIEWS
31. AB0321 EFFECT ON RETENTION RATES OF A NOVEL AUTOINJECTOR E-DEVICE IMPLEMENTED IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL; A MULTI-CENTRE STUDY
32. FRI0275 ONE-YEAR TREATMENT RETENTION OF SECUKINUMAB VERSUS TUMOR NECROSIS FACTOR INHIBITORS IN SPONDYLOARTHRITIS. RESULTS FROM FIVE NORDIC BIOLOGIC REGISTRIES
33. THU0197 Survival on Drug in Patients with Spondyloarthritis Receiving Certolizumab Pegol. Results from the Nationwide Swedish Rheumatology Quality Register
34. FRI0467 Work Disability in Early Systemic Sclerosis: A Longitudinal Population-Based Cohort Study
35. FRI0196 Costs in Relation to Disability, Disease Activity and Health-Related Quality of Life in Rheumatoid Arthritis
36. OP0278 Sick Leave and Disability Pension in Relation to First Initiation of Biologic Therapy across Indications: A Nationwide Cohort Study
37. SAT0352 Comparison of Nonradiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients – Baseline Characteristics and Development of Clinical Variables during Three Years of Anti-TNF Therapy in Clinical Practice
38. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
39. SAT0130 Defining the Optimal Biological Monotherapy in Rheumatoid Arthritis (RA): Network Meta-Analysis of Randomized Trials
40. SAT0047 Impact of Anti-Rheumatic Treatment on Immunogenicity of Pandemic H1N1 Influenza Vaccine in Patients with Arthritis
41. SAT0564 The Prevalence of Moderate to Severe Radiographically Verified Sacroiliitis and the Correlation with Health Status in Elderly Swedish Men - The Mros Study
42. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients
43. And now, e-publication bias
44. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden
45. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register
46. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
47. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.
48. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.